CN101657721B - 鉴定甲状腺疾病风险的方法 - Google Patents

鉴定甲状腺疾病风险的方法 Download PDF

Info

Publication number
CN101657721B
CN101657721B CN200880012149.4A CN200880012149A CN101657721B CN 101657721 B CN101657721 B CN 101657721B CN 200880012149 A CN200880012149 A CN 200880012149A CN 101657721 B CN101657721 B CN 101657721B
Authority
CN
China
Prior art keywords
thyroid
treatment
patients
patient
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880012149.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN101657721A (zh
Inventor
D·H·马戈林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to CN201810058824.2A priority Critical patent/CN108303546B/zh
Publication of CN101657721A publication Critical patent/CN101657721A/zh
Application granted granted Critical
Publication of CN101657721B publication Critical patent/CN101657721B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70592—CD52
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/046—Thyroid disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN200880012149.4A 2007-02-16 2008-02-15 鉴定甲状腺疾病风险的方法 Active CN101657721B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810058824.2A CN108303546B (zh) 2007-02-16 2008-02-15 鉴定甲状腺疾病风险的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90173207P 2007-02-16 2007-02-16
US60/901,732 2007-02-16
PCT/US2008/002047 WO2008103292A1 (en) 2007-02-16 2008-02-15 Method of identifying risk for thyroid disorder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810058824.2A Division CN108303546B (zh) 2007-02-16 2008-02-15 鉴定甲状腺疾病风险的方法

Publications (2)

Publication Number Publication Date
CN101657721A CN101657721A (zh) 2010-02-24
CN101657721B true CN101657721B (zh) 2018-02-23

Family

ID=39434244

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880012149.4A Active CN101657721B (zh) 2007-02-16 2008-02-15 鉴定甲状腺疾病风险的方法
CN201810058824.2A Active CN108303546B (zh) 2007-02-16 2008-02-15 鉴定甲状腺疾病风险的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810058824.2A Active CN108303546B (zh) 2007-02-16 2008-02-15 鉴定甲状腺疾病风险的方法

Country Status (21)

Country Link
US (3) US20100136587A1 (https=)
EP (2) EP2538217A1 (https=)
JP (2) JP5662684B2 (https=)
CN (2) CN101657721B (https=)
AU (1) AU2008219097B2 (https=)
BR (1) BRPI0807601B8 (https=)
CA (1) CA2678199A1 (https=)
CY (1) CY1118663T1 (https=)
DK (1) DK2130044T3 (https=)
ES (1) ES2612558T3 (https=)
HR (1) HRP20170121T1 (https=)
HU (1) HUE031421T2 (https=)
IL (2) IL200314A (https=)
LT (1) LT2130044T (https=)
MX (1) MX2009008642A (https=)
PL (1) PL2130044T3 (https=)
PT (1) PT2130044T (https=)
RS (1) RS55636B1 (https=)
RU (1) RU2013120485A (https=)
SI (1) SI2130044T1 (https=)
WO (1) WO2008103292A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
FR2934129B1 (fr) * 2008-07-24 2014-05-02 Oreal Procede de traitement cosmetique.
EP2335066B1 (en) * 2008-09-19 2016-12-28 University of Utah Research Foundation Methods for prediction of multiple sclerosis disease and therapy response
CN106257288A (zh) * 2016-08-15 2016-12-28 余洋 一种血清TPOAb IgG4水平检测方法
CN112312921A (zh) 2018-07-02 2021-02-02 美国西门子医学诊断股份有限公司 新型甲状腺过氧化物酶自身抗体免疫测定
KR102469743B1 (ko) 2020-06-10 2022-11-22 주식회사 타이로스코프 약물 복용에 따른 갑상선 기능 모니터링 방법, 이를 수행하는 모니터링 서버 및 사용자 단말
EP4001919A1 (en) * 2020-11-13 2022-05-25 Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal Predictive biomarkers of autoimmunity in patients treated with alemtuzumab
WO2024158259A1 (ko) * 2023-01-27 2024-08-02 주식회사 타이로스코프 대상에 대한 갑상선기능이상증의 예측방법 및 시스템

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB2265713A (en) * 1992-05-16 1993-10-06 R S R Limited Assay for autoantibodies against thyroglobulin or thyroid peroxidase
DE19710211C2 (de) * 1997-03-12 1999-12-16 Brahms Diagnostica Gmbh Verfahren zur Bestimmung von Schilddrüsen-Autoantikörpern
GB9823397D0 (en) * 1998-10-27 1998-12-23 Rsr Ltd Assays for thyroid autoantibodies
JP2008523785A (ja) * 2004-10-12 2008-07-10 カーランテック，インコーポレーテッド 神経変性、自己免疫脱髄、および糖尿病のウイルス病原に対する動物モデル系
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis;Coles A J et al;《Lancet》;19991113;第354卷(第9191期);1691-1695 *
自身免疫性甲状腺疾病患者甲状腺过氧化物酶抗体测定的临床意义;邬伟里等;《临床内科杂志》;20020430;第19卷;124-125 *

Also Published As

Publication number Publication date
JP5662684B2 (ja) 2015-02-04
JP2014149313A (ja) 2014-08-21
RU2013120485A (ru) 2014-11-20
BRPI0807601A2 (pt) 2014-05-06
MX2009008642A (es) 2009-10-20
LT2130044T (lt) 2017-02-10
CN101657721A (zh) 2010-02-24
AU2008219097B2 (en) 2011-06-23
CY1118663T1 (el) 2017-07-12
CN108303546B (zh) 2023-01-03
SI2130044T1 (sl) 2017-03-31
IL242391A (en) 2017-09-28
IL200314A0 (en) 2010-04-29
US9664688B2 (en) 2017-05-30
PL2130044T3 (pl) 2017-04-28
US20130095507A1 (en) 2013-04-18
EP2130044A1 (en) 2009-12-09
EP2130044B1 (en) 2016-10-26
RS55636B1 (sr) 2017-06-30
CN108303546A (zh) 2018-07-20
US20100136587A1 (en) 2010-06-03
BRPI0807601B1 (pt) 2021-02-23
HK1257419A1 (zh) 2019-10-18
US20170307629A1 (en) 2017-10-26
DK2130044T3 (en) 2017-02-06
BRPI0807601B8 (pt) 2021-07-27
JP2010519512A (ja) 2010-06-03
ES2612558T3 (es) 2017-05-17
HRP20170121T1 (hr) 2017-03-24
IL200314A (en) 2015-11-30
WO2008103292A1 (en) 2008-08-28
CA2678199A1 (en) 2008-08-28
US10648986B2 (en) 2020-05-12
AU2008219097A1 (en) 2008-08-28
EP2538217A1 (en) 2012-12-26
JP6058585B2 (ja) 2017-01-11
HUE031421T2 (hu) 2017-07-28
RU2009134313A (ru) 2011-03-27
PT2130044T (pt) 2017-02-03

Similar Documents

Publication Publication Date Title
US10648986B2 (en) Method of identifying risk for thyroid disorder
US9783600B2 (en) Apolipoprotein C3 (ApoCIII) antagonists and methods of their use to remove ApoCIII inhibition of lipoprotein lipase (LPL)
JPH09507578A (ja) インスリン受容体チロシンキナーゼインヒビターに対するアンタゴニスト
EP1643894A2 (en) Methods, kits and antibodies for detecting parathyroid hormone
EP1181554B1 (en) Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
RU2707755C2 (ru) Способ прогнозирования риска возникновения рака или диагностирования рака у женщины
EP4176267B1 (en) Amh and/or inhibin b as a biomarker for an effect of a treatment to improve male fertility
HK1257419B (en) Method of identifying risk for thyroid disorder
RU2575560C2 (ru) Способ выявления риска расстройства щитовидной железы
EP1120651A1 (en) Method and reagent for assaying arthritis-associated melanotransferrin
HK1180393A (en) Method of identifying risk for thyroid disorder
Gauna et al. Immunological aspects of Graves’ disease patients in different clinical stages
US7465703B1 (en) Methods and kits useful for guiding osteoporosis related therapy
Xin et al. The clinical characteristics and treatment response of myasthenia gravis with positive thyroid peroxidase antibody or thyroid globulin antibody
JP2012523002A (ja) 自己抗体関連疾患の検出および／または治療
Condon Improving Outcomes in Glomerulonephritis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant